Table of Contents
Supplemental Table 1. Baseline characteristics by absolute decline in eGFR between baseline and Week 2 in DAPA-CKD (N=4,157)...2 Supplementary Figure 1. Acute decline in eGFR ≥30% or <30% in the dapagliflozin group (panel A) and placebo group (panel B)...4 Supplementary Figure 2. eGFR by acute absolute decline categories for dapagliflozin and placebo. Panel A shows the dapagliflozin group; panel B the placebo group and panel C the annual eGFR decline from Week 2 to end of treatment decline as a function of acute
changes in eGFR in the placebo and dapagliflozin group...5
Supplementary Figure 3. Risk of primary and secondary outcomes with acute decrease in
eGFR in the dapagliflozin group...7
Supplementary Figure 4. Treatment effect of dapagliflozin on primary and secondary
outcomes as function of change in eGFR...8
Supplemental Table 1. Baseline characteristics by absolute decline in eGFR between baseline and Week 2 in DAPA-CKD (N=4,157)
Dapagliflozin (N=2,075)
Placebo (N=2,082)
≤0 mL/min/1.73m2 decline
>0–≤3 mL/min/1.73m2 decline
>3 mL/min/1.73m2 decline
≤0 mL/min/1.73m2 decline
>0–≤3 mL/min/1.73m2 decline
>3 mL/min/1.73m2 decline
n=448 n=490 n=1,137 p-value n=985 n=521 n=576 p-value
Age, years 61.1 (12.7) 61.1 (12.4) 62.7 (11.4) 0.013 61.9 (11.8) 62.2 (13.0) 61.6 (11.8) 0.688
Female sex, n (%) 153 (34.2) 158 (32.2) 373 (32.8) 0.813 297 (30.2) 174 (33.4) 226 (39.2) 0.001
Race*, n (%) 0.008 0.176
White 226 (50.5) 224 (49.8) 628 (55.2) 560 (56.9) 278 (53.4) 300 (52.1)
Black or African American 13 (2.9) 23 (4.7) 68 (6.0) 35 (3.6) 21 (4.0) 29 (5.0)
Asian 171 (38.2) 185 (37.8) 347 (30.5) 309 (31.4) 186 (35.7) 189 (32.8)
Other 38 (8.5) 38 (7.8) 94 (8.3) 81 (8.2) 36 (6.9) 58 (10.1)
Current smoker, n (%) 64 (14.3) 73 (14.9) 134 (11.8) 0.161 141 (14.3) 67 (12.9) 82 (14.2) 0.726
Body mass index (kg/m2) 28.7 (5.5) 29.5 (6.2) 29.7 (6.2) 0.009 30.0 (6.1) 29.3 (6.7) 29.6 (6.3) 0.179
Blood pressure, mmHg
Systolic 134.7 (16.5) 137.3 (17.0) 137.5 (18.0) 0.012 136.1 (16.9) 138.6 (17.7) 139.0 (17.6) 0.001
Diastolic 77.6 (10.0) 78.2 (11.3) 77.1 (10.6) 0.176 77.3 (10.4) 77.4 (10.7) 78.1 (9.9) 0.311
HbA1c, % 7.2 (1.9) 6.7 (1.5) 7.2 (1.7) 0.000 7.0 (1.7) 7.0 (1.8) 7.1 (1.7) 0.333
Median urinary albumin-to-creatinine ratio† (Q1–Q3)
892.5 443, 1819
997.2 481, 1949
984.0 478, 1907
0.285 858.5
448, 1690
946.5 504, 1816
1062.5 521, 2077
0.001 Estimated glomerular filtration rate
(mL/min/1.73m2) 43.9 (12.5) 38.9 (11.0) 45.0 (12.4) 0.000 42.9 (12.6) 40.2 (11.9) 45.9 (12.0) 0.000
Type 2 diabetes, n (%) 292 (65.2) 304 (62.0) 811 (71.3) 0.000 657 (66.7) 350 (67.2) 404 (70.1) 0.354
Cardiovascular disease‡, n (%) 164 (36.6) 168 (34.3) 458 (40.3) 0.057 367 (37.3) 200 (38.4) 203 (35.2) 0.543
Heart failure, n (%) 60 (13.4) 50 (10.2) 118 (10.4) 0.184 117 (11.9) 50 (9.6) 58 (10.1) 0.318
Prior medication, n (%)
ACE inhibitor 149 (33.3) 134 (27.3) 370 (32.5) 0.077 299 (30.4) 168 (32.2) 187 (32.5) 0.614
ARB 289 (64.5) 347 (70.8) 755 (66.4) 0.097 664 (67.4) 336 (64.5) 385 (66.8) 0.512
Diuretic 161 (35.9) 207 (42.2) 533 (46.9) 0.000 421 (42.7) 231 (44.3) 273 (47.4) 0.203
*Race was reported by the investigators; ‘other’ includes Native Hawaiian or other Pacific Islander, American Indian or Alaska Native, and other. †The albumin-to-creatinine ratio was calculated with albumin measured in milligrams and creatinine measured in grams. ‡Cardiovascular disease was defined as a history of peripheral artery disease, angina pectoris, myocardial infarction,
percutaneous coronary intervention, coronary-artery bypass grafting, heart failure, valvular heart disease, abdominal aorta aneurysm, atrial fibrillation, atrial flutter, ischemic stroke, transient ischemic attack, hemorrhagic stroke, carotid artery stenosis, cardiac-pacemaker insertion, vascular stent, coronary-artery stenosis, ventricular arrhythmia, implantable cardioverter–defibrillator, noncoronary revascularization, or surgical amputation.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker
Supplementary Figure 1. Acute decline in eGFR ≥30% or <30% in the dapagliflozin group
(panel A) and placebo group (panel B)
Supplementary Figure 2. eGFR by acute absolute decline categories for dapagliflozin and placebo. Panel A shows the dapagliflozin group; panel B the placebo group and panel C the annual eGFR decline from Week 2 to end of treatment decline as a function of acute
changes in eGFR in the placebo and dapagliflozin group.
Chronic slope shown
P-values indicate the statistical significance of the association between the acute eGFR change (%) and long-term eGFR decline (mL/min/1.73m2/year)
